Is tibolone a viable alternative to HT?

Contemporary Ob/Gyn

Volumn 48, Issue 8, 2003, Pages 54-68

  Speroff, Leon ^a   Clarkson, Thomas B ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2442557734     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Lindsay R, Hart DM, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J. 1980;280:1207-1209.
2. MacLennan AH, Henry D, Hills S, et al., eds. Oral oestrogen replacement therapy versus placebo for hot flushes. Farquhar C, Cooke I, Barlow D, eds. Menstrual Disorders Module of the Cochrane Database of Systematic Reviews. Oxford: Cochrane Library Update Software; 2000.
3. Trevoux R, Dieulangard P, Blum A. Efficacy and safety of Org OD 14 in the treatment of climacteric complaints. Maturitas. 1983;5:89-96.
4. Volpe A, Facchinetti F, Grasso A, et al. Benefits and risks of different hormonal replacement therapies in postmenopausal women. Maturitas. 1986;8:327-334.
5. Siseles NO, Halperin H, Benencia HJ, et al. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Maturitas. 1995;21:201-210.
6. Nathorst-Boos J, Hammar M. Effect on sexual life- a comparison between tibolone and a continuous estradiol-norethlsterone acetate regimen. Maturitas. 1997;26:15-20.
7. Hammar M, Christau S, Nathorst-Boos J, et al. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998;105:904-911.
8. Al-Azzawi F, Wahab M, Habiba M, et al. Continuous combined hormone replacement therapy compared with tibolone. Obstet Gynecol. 1999;93:258-264.
9. Kokcu A, Cetinkaya MB, Yanik F, et al. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas. 2000;36:75-80.
10. Landgren MB, Bennink HJ, Helmond FA, et al. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG. 2002;109:1109-1114.
11. Taskin O, Yalcinoglu Al, Kucuk S, et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril. 1997;67:40-45.
12. Crona N, Silfverstolpe G, Samsioe G. A double-blind cross-over study on the effects of Org OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol (Copenh). 1983:102:451-455.
13. Rymer J, Chapman MG, Fogelman I, et al. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas. 1994;18:127-133.
14. Botsis D, Kassanos D, Kalogirou D, et al. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison. Maturitas. 1997;26:57-62.
15. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arous-ability in postmenopausal women. Climacteric. 2001;4:28-41.
16. Mendoza N, Suarez AM, Alamo F, et al. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause. Maturitas. 2000;37:37-43.
17. Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas. 2000;34:161-168.
18. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG. 2002;109:886-893.
19. Egarter C, Topcuoglu A, Vogl S, et al. Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women. Acta Obstet Gynecol Scand. 2002;81:649-653.
20. Palacios S, Menendez C, Jurado AR, et al. Changes in sex behaviour after menopause: effects of tibolone. Maturitas. 1995;22:155-161.
21. Doren M, Rubig A, Coelingh Bennink HJ, et al. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 2001;75:554-559.
22. Fluck E, File SE, Rymer J. Cognitive effects of 10 years of hormone-replacement therapy with tibolone. J Clin Psychopharmacol. 2002;22:62-67.
23. Bukulmez O, Al A, Gurdal H, et al. Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: a prospective randomized trial. Fertil Steril. 2001;75:737-743.
24. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA. 1999;281:1197-1202.
25. Maki PM, Resnik SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging. 2000;21:373-383.
26. Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol. 1993;128:259-262.
27. Milner MH, Sinnott MM, Cooke TM, et al. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol. 1996;87:593-599.
28. Cagnacci A, Maiius E, Tuveri F, et al. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab. 1997;82:251-253.
29. Lloyd G, McGing E, Cooper A, et al. A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens. 2000;14:99-104.
30. Ginsburg J, Prelevic GM. Antiatherosclerotic effects of tibolone. Menopause. 2001;8:79-80.
31. Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with tibolone in postmenopausal women: results of too randomized double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab. 2001;86:4717-4726.
32. Barnes JF, Farish E, Rankin M, et al. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis. 2002;160:185-193.
33. von Eckardstein A, Schmiddem K, Hovels A, et al. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis. 2001;159:433-439.
34. Haenggi W, Bersinger NA, Mueller MD, et al. Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone. Gynecol Endocrinol. 1999;13:202-205.
35. Farish E, Barnes JF, Rolton HA, et al. Effects of tibolone on lipoprotein(a) and HDL subtractions. Maturitas. 1994;20:215-219.
36. Lloyd GW, Patel NR, McGing EA, et al. Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina. Int J Clin Pract. 1998;52:155-157.
37. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab. 1997;82:1752-1756.
38. Castelo-Branco C, Casals E, Figueras F, et al. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins Al and B. Menopause. 1999;6:92-97.
39. Kloosterboer HJ, Benedek-Jaszmann LJ, Kicovic PM. Long-term effects of Org OD 14 on lipid metabolism in post-menopausal women. Maturitas. 1990;12:37-42.
40. Pan HA, Wang ST, Chen CH, et al. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy. Climacteric. 2002;5:259-265.
41. Cetinkaya MB, Alper T, Kokcu A, et al. Tibolone versus four estrogen replacement therapy protocols and plasma lipid levels in postmenopausal women. Int J Gynaecol Obstet. 2002;79:17-23.
42. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscl Thromb Vase Biol. 2001;21:13-27.
43. von Eckardstein A, Crook D, Elbers J, et al. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin Endocrinol (Oxf). 2003;58:49-58.
44. Garnero P, Jamin C, Benhamou CL, et al. Effects of tibolone and combined 17beta-estradiol and norethis-terone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. Hum Reprod. 2002;17:2748-2753.
45. Prelevic GM, Kwong P, Byrne DJ, et al. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril. 2002;77:945-951.
46. Celik H, Ayar A, Tug N, et al. Effects of tibolone on plasma homocysteine levels in postmenopausal women. Fertil Steril. 2002;78:347-350.
47. Morris EP, Denton ER, Robinson J, et al. High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure. Climacteric. 1999;2:13-20.
48. de Kleijn MJ, Wilmink HW, Bots ML, et al. Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women. Atherosclerosis. 2001;159:357-365.
49. Ceballos C, Ribes C, Amado JA, et al. Venous endothelial function in postmenopausal women after six months of tibolone therapy. Maturitas. 2001;39:63-70.
50. Manzella D, Fornaro F, Carbonella M, et al. Effect of tibolone administration on heart rate variability and free fatty acid levels in postmenopausal women. Fertil Steril. 2002;78:1005-1009.
51. Simoncini T, Genazzani AR. Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol. 2000;162:87-94.
52. de Beer F, Smelt AH, Van Vark LC, et al. The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia. J Intern Med. 2002;251:148-155.
53. Prelevic GM, Beljic T, Balint-Peric L, et al. Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus. Maturitas. 1998;28:271-276.
54. Wiegratz I, Starflinger F, Tetzloff W, et al. Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women. Maturitas. 2002;41:133-141.
55. Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem. 1990;35:535-541.
56. Tang B, Markiewicz L, Kloosterboer HJ, et al. Human endometrial 3 beta-hydroxysteroid dehydroge-nase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol. 1993;45:345-351.
57. Punnonen R, Liukko P, Cortes-Prieto J, et al. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in postmenopausal and oophorectomized women. Maturitas. 1984;5:281-286.
58. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, et al. Org OD 14 and the endometrium. Maturitas. 1991;13:243-251.
59. Ginsburg J, Prelevic G, Butler D, et al. Clinical experience with tibolone (Livial) over 8 years. Maturitas. 1995;21:71-76.
60. Meuwissen JH, Wiegerinck MA, Haverkorn MJ. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas. 1995;21:121-125.
61. Egarter C, Sator M, Berghammer P, et al. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. Int J Gynaecol Obstet. 1999;64:281-286.
62. Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric. 2001;4:203-208.
63. Ginsburg J, Prelevic GM. Cause of vaginal bleeding in postmenopausal women taking tibolone. Maturitas. 1996;24:107-110.
64. Helmond FA, Kloosterboer HJ. Safety and tolerability profile of Livial. In: Genazzani AR, ed. Hormone Replacement Therapy and Cancer. The Current Status of Research and Practice. Boca Raton: The Parthenon Publishing Group; 2002:252-256.
65. Wu MH, Pan HA, Wang ST, et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric. 2001;4:314-319.
66. Rymer J, Fogelman I, Chapman MG. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol. 1994;101:53-56.
67. Berning B, van Kuijk C, Benink HJ, et al. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas. 2000;35:81-88.
68. Hanggi W, Lippuner K, Riesen W, et al. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol. 1997;104:708-717.
69. Fedele L, Bianchi S, Raffaelli R, et al. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol. 2000;88:91-94.
70. Gregoriou 0, Konidaris S, Botsis D, et al. Long term effects of tibolone on postmenopausal women with uterine myomas. Maturitas. 2001;40:95-99.
71. Simsek T, Karakus C, Trak B. impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. Maturitas. 2002;42:243-246.
72. Palomba S, Affinito P, Tommaselli GA, et al. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril. 1998;70:111-118.
73. Santner SJ, Feil PD, Santen RJ. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus aromatase pathway. J Clin Endocrinol Metab. 1984;59:29-33.
74. Chetrite GS, Cortes-Prieto J, Philippe JC, et al. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol. 2000;72:23-27.
75. Pasqualini JR, Chetrite G. Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells. J Steroid Biochem Mol Biol. 2001;78:21-24.
76. Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res. 1997;17:135-140.
77. Chetrite GS, Kloosterboer HJ, Philippe JC, et al. Effects of Org OD14 (Livial) and its metabolites on 17-beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Anticancer Res. 1999;19:261-267.
78. van de Ven J, Donker GH, Sprong M, et al. Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells. J Steroid Biochem Mol Biol. 2002;81:237-247.
79. Purohit A, Malini B, Hooymans C, et al. Inhibition of oestrone sulphatase activity by tibolone and its metabolites. Horm Metab Res. 2002;1:1-6.
80. Chetrite GS, Kloosterboer HJ, Philippe JC, et al. Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hor-mone-dependent McF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines. Anticancer Res. 1999;19:269-275.
81. Kloosterboer HJ. Endocrine prevention of breast: any role for tibolone? Eur J Cancer. 2002;(38 suppl 6):S24-S25.
82. Gompel A, Siromachkova M, Lombet A, et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer. 2000;36:76-77.
83. de Gooyer ME, Kleyn GT, Smits KC, et al. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol. 2001;183:55-62.
84. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest. 2000;20:101-107.
85. Colacurci N, Fornaro F, De Franciscis P, et al. Effects of different types of hormone replacement therapy on mammographic density. Maturitas. 2001;40:159-164.
86. Sendag F, Coson Terek M, Ozsener S, et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril. 2001;76:445-450.
87. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002;186:717-722.
88. Egarter C, Eppel W, Vogel S, et al. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas. 2001;40:165-171.
89. Berning B, Kuijk CV, Kuiper JW, et al. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone. 1996;19:395-399.
90. Lippuner K, Haenggi W, Birkhaeuser MH, et al. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. J Bone Miner Res. 1997;12:806-812.
91. Studd J, Arnala I, Kicovic PM, et al. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol. 1998;92:574-579.
92. Milner M, Harrison RF, Gilligan et al. Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Menopause. 2000;7:327-333.
93. Rymer J, Robinson J, Fogelman I. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos Int. 2001;12:478-483.
94. Ederveen AG, Kloosterboer HJ. Tibolone exerts an estrogenic effect on bone leading to prevention of bone loss and reduction in bone resorption in ovariectomized rats. Osteoporos Int. 1999;8:95.
95. Palomba S, Morelli M, Di Carlo C, et al. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone. Fertil Steril. 2002;78:63-68.
96. Meeuwsen IB, Samson MM, Duursma SA, et al. The effect of tibolone on fat mass, fat-free mass, and total body water in postmenopausal women. Endocrinology. 2001;142:4813-4817.